Fujirebio announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse G pTau 217/ß-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test for ...

(BUSINESS WIRE )--Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company's Lumipulse ® G pTau 217/β-Amyloid 1-42 Plasma Ratio in ...

The ability to detect brain-derived pTau species directly from blood represents a transformative step in early detection Phosphorylated tau has emerged as a critical biomarker for early detection ...

MALVERN, Pa., & TOKYO — Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse ® G pTau 217/β-Amyloid 1-42 Plasma Ratio ...

The new additions to the CNS Disease 120 Panel are specifically designed to detect brain-derived forms of pTau, overcoming the limitations of current assays that cannot distinguish between ...